Eli Lilly & CO Form 4 insider transactions

J. Erik Fyrwald, a director at Eli Lilly & Co, acquired 13.358 shares of common stock at $742.35 per share under the company's Directors' Deferral Plan.

Director Ralph Alvarez acquired 15.828 shares of Eli Lilly & Co common stock at $742.35 per share through the Lilly Directors' Deferral Plan.

Gabrielle Sulzberger, a director at Eli Lilly & Co, acquired shares of common stock through a deferral plan in lieu of cash compensation.

Director Juan R. Luciano acquired 19,042 shares of Eli Lilly common stock through a deferral plan, as reported in a recent SEC filing.

Kimberly H. Johnson, a director at Eli Lilly & Co, acquired 12,409 shares of common stock through a deferral plan.

Mary Lynne Hedley, a director at Eli Lilly, acquired shares of common stock through a deferral plan, while also disposing of shares held in a trust.

Director Ralph Alvarez acquired 15,083 shares of Eli Lilly common stock through a deferral plan, while also disposing of 54,689.496 shares.

Director Karen Walker acquired 302.53 shares of Eli Lilly common stock at a price of $727.2 per share on November 18, 2024.

Gabrielle Sulzberger, a director at Eli Lilly, acquired shares of common stock through a deferral plan, increasing her holdings.

Director Juan R. Luciano of Eli Lilly & Co. acquired shares through a deferral plan, increasing his holdings.

Director William G. Kaelin Jr. acquired shares of Eli Lilly & Co. common stock on November 18, 2024.

Director Kimberly H. Johnson acquired shares of Eli Lilly stock through a deferral plan, increasing her holdings.

Director Jamere Jackson acquired 302.53 shares of Eli Lilly & Co. common stock at a price of $727.2 per share on November 18, 2024.

Mary Lynne Hedley, a director at Eli Lilly & Co, acquired shares of common stock through a deferral plan and a trust.

Director J. Erik Fyrwald of Eli Lilly & Co. acquired shares of common stock on November 18, 2024.

Director Katherine Baicker acquired shares of Eli Lilly & Co. common stock in a recent transaction.

Director Ralph Alvarez of Eli Lilly & Co. acquired shares of common stock through a deferral plan, increasing his holdings.

Donald A. Zakrowski, SVP, Finance, & CAO of Eli Lilly, sold 900 shares of common stock at $803.38 per share on November 8, 2024, under a pre-arranged 10b5-1 trading plan.

Eli Lilly's EVP & CFO, Lucas Montarce, executed transactions involving company stock, including the vesting of restricted stock units and the subsequent sale of shares to cover taxes.

Executive Vice President Edgardo Hernandez of Eli Lilly & Co. reported the acquisition and disposal of company stock and restricted stock units on November 1, 2024.

Executive Vice President of Human Resources and Diversity at Eli Lilly, Eric Dozier, reports the acquisition and disposal of company stock and restricted stock units.

Eli Lilly's Executive Vice President and President of Lilly Oncology, Jacob Van Naarden, transferred 4,302 shares of common stock to his spouse.

Gabrielle Sulzberger, a director at Eli Lilly & Co, acquired 11 shares of common stock through a deferral plan.

Director Juan R. Luciano acquired 16 shares of Eli Lilly common stock at $906.13 per share through a deferral plan.

Kimberly H. Johnson, a director at Eli Lilly & Co, acquired 11 shares of common stock through a deferral plan.

Mary Lynne Hedley, a director at Eli Lilly, acquired 11 shares of common stock through a deferral plan.

Director Ralph Alvarez acquired 13 shares of Eli Lilly common stock through a deferral plan, at a price of $906.13 per share.

Gabrielle Sulzberger, a director at Eli Lilly, acquired 11 shares of common stock through a deferral plan.

Director Juan R. Luciano acquired 16 shares of Eli Lilly common stock through a deferral plan, at a price of $923.54 per share.

Director Kimberly H. Johnson acquired 10 shares of Eli Lilly common stock through a deferral plan, as reported in a recent SEC filing.